Proviva Pharma Team
I am the founder of Proviva Pharm and Professor of Biomedical Engineering, Artificial Cells and Organs, Physiology, Experimental Medicine and Surgery in the Faculty of Medicine, at McGill University, Montreal, Quebec, Canada. I am the co-founder of Micropharma and MangoGen Pharma. I have contributed to the advancement and understanding the human microbiome, probiotic formulations for use in neurological disorders such as Alzheimer’s, Parkinson’s, aging, metabolic syndrome, obesity, cardiovascular diseases, medical devices such as next generation of stents, film dressing and targeted delivery of drugs, live cells, and therapeutic molecules. I am the author of more than 350 research papers/abstracts and several book chapters, research, and other scholarly articles. My publication list includes 72 approved/pending patents and 3 edited books. I am the winner of more than 30 international awards including “Medial for Outstanding Contribution to the Advancement of Science”, Fraser, Monat and McPherson Award, Canadian Institute of Health Research Investigator Award, FRSQ Chercheure‐Boursière, Shandong China
I have over thirty (30) years of experience with investing in the fitness, health, nutrition, diet, and bioscience industries. I was the youngest Senior Vice President in the history of San Francisco based Dean Witter Reynolds which later was acquired by Morgan Stanley. I am responsible for the completion with investing of over three hundred million USD (300,000,000.00), in privately held health related enterprises. In addition, I have been responsible for the deployment of well over two and one half billion dollars USD (2,500,000,000.00) in publicly traded health sector opportunities. I have a deep passion for helping people enjoy a long and healthier life. I have been an owner, investor and innovator within the health, nutrition, diet, and fitness industry for over three decades. I am the President of BFD diet.
I completed my education in China (BSc and MS) and in Canada (PhD), and had postdoctoral training in tissue repair and regeneration. My previous R&D experiences in biomedical engineering are extensive, covering biomaterials, drug delivery, human microbiome and probiotics, artificial cells and cell therapy, tissue engineering. I have produced a large number of high impactful publications; some of my findings were highly recognized in the academic community and translated to clinical products. I have won a number of prestigious awards.